There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure.

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial / Mebazaa, Alexandre; Davison, Beth; Chioncel, Ovidiu; Cohen-Solal, Alain; Diaz, Rafael; Filippatos, Gerasimos; Metra, Marco; Ponikowski, Piotr; Sliwa, Karen; Voors, Adriaan A; Edwards, Christopher; Novosadova, Maria; Takagi, Koji; Damasceno, Albertino; Saidu, Hadiza; Gayat, Etienne; Pang, Peter S; Celutkiene, Jelena; Cotter, Gad. - In: THE LANCET. - ISSN 0140-6736. - (2022). [10.1016/S0140-6736(22)02076-1]

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

Metra, Marco;
2022-01-01

Abstract

There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/194064
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 744
  • ???jsp.display-item.citation.isi??? 671
social impact